Controlling arachidonic acid metabolic network: From single-to multi-target inhibitors of key enzymes

Yaoxue Xuebao

Volumn 44, Issue 3, 2009, Pages 231-241

  Liu, Ying ^a   Chen, Zheng ^a   Shang, Er Chang ^a   Yang, Kun ^a   Wei, Deng Guo ^a   Zhou, Lu ^a   Jiang, Xiao Lu ^a   He, Chong ^a   Lai, Lu Hua ^a  

^a PEKING UNIVERSITY   (China)

Author keywords

Arachidonic acid metabolic network; Key enzymes; Multi target inhibitors; Single target inhibitors

Indexed keywords

6 METHOXY 2 NAPHTHYLACETIC ACID; ACETYLSALICYLIC ACID; ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONIC ACID; CELECOXIB; DICLOFENAC; IBUPROFEN; INDOMETACIN; LICOFELONE; MELOXICAM; METHYLTESTOSTERONE; NAPROXEN; NIMESULIDE; PARACETAMOL; PHOSPHOLIPASE A2; PROSTAGLANDIN SYNTHASE; ROFECOXIB;

ANTIINFLAMMATORY ACTIVITY; ARACHIDONIC ACID METABOLISM; CONTROLLED STUDY; DRUG INHIBITION; DRUG STRUCTURE; ENZYME METABOLISM; IC 50; PROSTAGLANDIN SYNTHESIS INHIBITION; REVIEW;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARACHIDONATE 5-LIPOXYGENASE; ARACHIDONIC ACID; CYCLOOXYGENASE INHIBITORS; DRUG DELIVERY SYSTEMS; EPOXIDE HYDROLASES; HUMANS; INFLAMMATION; METABOLIC NETWORKS AND PATHWAYS; PHOSPHOLIPASES A2; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 67249163020     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Bolognesi M, Minarini A, Rosini M, et al. From dual binding site acetylcholinesterase inbibitors to multi-target-directed ligands (MTDLs): A step forward in the treatment of Alzheimer's disease [J]. Mini Rev Med Chem, 2008, 8: 960-967.
2. Bolognesi ML, Banal R, Bartolini M, et al. Novel class of quinone-bearing polyamines as multi-target-directed ligands to combat Alzheimer's disease [J]. J Med Chem, 2007, 50: 4882-4897.
3. Chen CH, Liu DZ, Fang HW, et al. Evaluation of multi-target and single-target liposomal drugs for the treatment of gastric cancer [J]. Biosci Biotechnol Biocheni, 2008, 72: 1586-1594.
4. Petrelli A, Giordano S. From single-to multi-target drugs in cancer therapy: When aspecificity becomes an advantage [J]. Curr Med Chem, 2008, 15: 422-432.
5. Wong EH, Nikam SS, Shahid M. Multi- and single-target agents for major psychiatric diseases: Therapeutic opportunities and challenges [J]. Curr Opin Investig Drugs, 2008,9: 28-36.
6. Korcsmáros T, Szalay M, Böde C, et al. How to design multi-target drugs: Target search options in cellular networks [J]. Invited Review to Expert Opinion on Drug Discovery, 2007, 2: 1-10.
7. Csermely P, Agoston V, Pongor S. The efficiency of multi- target drugs: The network approach might help drug design [J]. Trends Pharmacol Sci, 2005, 26: 178-182.
8. Morphy R, Rankovic Z. Fragments, network biology and designing multiple ligands [J]. Drug Discov Today, 2007, 12: 156-160.
9. Meyer MC, Rastogi P. Beckett CS, et al. Phospholipase A(2) inhibitors as potential anti-inflammatory agents [J]. Curr Pharm Des, 2005, 11: 1301-1312.
10. 2 inhibitors [J]. Nat Immunol, 2000, 1: 13-15.
11. Vadas P, Hay JB. Secretion of a hyperemia-inducing moiety by mitogen or glycogen stimulated mononuclear inflammatory cells of sheep and rabbit [J]. Int Arch Allergy Appl Immunol, 1980, 62: 142-151.
12. Street IP, Lin HK, Laliberte F, et al. Slow-binding and tight- binding inhibitors of the 85-kDa human phospholipase-A2 [J]. Biochemistry, 1993, 32: 5935-5940.
13. Burke JR, Davern LB, Stanley PL, et al. BMS-229724 is a tight-binding inhibitor of cytosolic phospholipase A2 that acts at the lipid/water interface and possesses anti-inflammatory activity in skin inflammation models [JJ. J Pharmacol Exp Ther, 2001, 298: 376-385.
14. Lehr M. Synthesis, biological evaluation, and structure- activity relationships of 3-acylindole-2-carboxylic acids as inhibitors of the cytosolic phospholipase A2 [J]. J Med Chem, 1997, 40: 2694-2705.
15. Lehr M, Klimt M, Elfringhoff AS. Novel 3-dodecanoylin- dole-2-carboxylic acid inhibitors of cytosolic phospholipase A(2) [J]. Bioorg Med Chem Lett, 2001, 11: 2569-2572.
16. Griessbach K, Klimt M, Elfringhoff AS, et al. Structure- activity relationship studies of 1-substituted 3-dodecanoylin- dole-2-carboxylic acids as inhibitors of cytosolic phospholipase A(2)-mediated arachidonic acid release in intact platelets [J]. Arch Pharm, 2003, 335: 547-555.
17. Ludwig J, Bovens S. Brauch C, et al. Design and synthesis of 1-indol-l-yl-propan-2-ones as inhibitors of human cytosolic phospholipase A(2)alpha [J]. J Med Chem, 2006, 49: 2611-2620.
18. Hess M, Elfringhoff AS, Lehr M. l-(5-Carboxy-and 5-car-bamoylindol-l-yl) propan-2-ones as inhibitors of human cytosolic phospholipase A2alpha: Bioisosteric replacement of the carboxylic acid and carboxaniide moiety [J]. Bioorg Med Chem, 2007, 15: 2883-2891.
19. McKew JC, Lee KL, Shen MW, et al. Indole cytosolic phospholipase A2 alpha inhibitors: Discovery and in vitro and in viva characterization of 4-{3-[5-chloro-2-(2-{[(3,4-dichloroben zyl) sulfonyl] amino} ethyl)-1 -(diphenylmethyl)-1H-indol-3-yl] propyl}benzoic acid, efipladib [J]. J Med Chem, 2008, 51: 3388-3413.
20. Ono T, Yamada K, Chikazawa Y, et al. Characterization of a novel inhibitor of cytosolic phospholipase A2alpha, pyrrophenone [J]. BiochemJ, 2002, 363: 727-735.
21. Beaton HG, Bennion C, Connolly S, et al. Discovery of new non-phospholipid inhibitors of the secretory phospholipases A2 [J]. J Med Chem, 1994, 37: 557-559.
22. Cha SS, Lee D, Adams J, et al. High-resolution X-ray crystallography reveals precise binding interactions between human nonpancreatic secreted phospholipase A2 and a highly potent inhibitor (FPL67O47XX) [J]. J Med Chem, 1996, 39: 3878-3881.
23. Iwama S, Segawa M, Fujii 5, et al. Design and synthesis of new secretory phospholipase A2 inhibitor of a phospholipid analog [J]. Bioorg Med Chem Lett, 1998, 8: 3495-3498.
24. Lemahieu RA, Carson M, Han RJ, et al. N-(carboxymethyl)n-[3, 5-bis(decyloxy)-phenyl]glycine (RO-23-9358) -a potent inhibitor of secretory phospholipases-A2 with antiinflammatory activity [J]. J Med Chem, 1993, 36: 3029-3031.
25. Traxnposch KM, Steiner SA, Stanley PL, et al. Novel inhibitor of phospholipase-A2 with topical anti-inflammatory activity [J). Biochem Biophys Res Commun, 1992, 189: 272-279.
26. Schevitz RW, Bach NJ, Carlson DG et al. Structure-based design of the first potent and selective inhibitor of human nonpancreatic secretory phospholipase A2 [J]. Nat Struct Biol, 1995, 2: 458-465.
27. Zhou L, Fang C, Wei P, et al Chemically induced dimerization of human nonpancreatic secretory phospholipase A2 by bis indole derivatives [J]. J Med Chem, 2008, 51: 3360-3366.
28. Samuelsson B, Morgenstern R, Jakobsson PJ. Membrane prostaglandin E synthase-1: A novel therapeutic target [J]. Pharmacol Rev, 2007, 59: 207-224.
29. Bazan. NG COX-2 as a multifunctional neuronal modulator [J]. NatMed, 2001,7: 414-415.
30. Thoren S, Jakobsson PJ. Coordinate up- and down-regulation of glutathione-dependent prostaglandin E synthase and cyclooxygenase-2 in A549 cells. Inhibition by NS-398 and leukotriene C-4 [J]. Eur J Biochem, 2000, 267: 6428-6434.
31. Riendeau D, Aspiotis R, Ethier D, et al. Inhibitors of the inducible microsomal prostaglandin E2 synthase (mPGES-l) derived from MK-886 Ii). Bioorg Med Chem Lett, 2005, 15: 3352-3355.
32. Xu DG Rowland SE, Clark P, et al. MF63 [2-(6-chloro-1H- phenanthro [9, 10-d] imidazol-2-yl)-isophthalonitrile], a selective microsomal prostaglandin E synthase-1 inhibitor, relieves pyresis and pain in preclinical models of inflammation [J]. J Pharmacol Exp Ther, 2008, 326: 754-763.
33. Deasy BM, O'Sullivan-Coyne G, O'Donovan TR. et al. Cyclooxygenase-2 inhibitors demonstrate anti-proliferative effects in oesophageal cancer cells by prostaglandin E-2-independent mechanisms [J]. Cancer Lett, 2007, 256: 246-258.
34. Prasit P, Wang Z, Brideau C, et al. The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)- furanone], an orally active cyclooxygenase-2 inhibitor [J]. Bioorg Med Chem Lett, 1999, 9: 1773-1778.
35. Moh JH, Choi YH, Lim KM, et al. A prodrug approach to COX-2 inhibitors with methylsulfone [J]. Bioorg Med Chem Lett, 2004, 14: 1757-1760.
36. Singh SK, Vobbalareddy 5, Kalleda SR, et al. Identification of 2-hydroxymethyl-4-15-(4-methoxyphenyl)-3-trifluoromethyl-pyrazol-1-yl] -N-propionylbenzenesulfonamide sodium as a potential COX-2 inhibitor for oral and parenteral administration [C]. 225th National Meeting of the American-Chemical-Society, New Orleans, 2003: 8626-8634.
37. Khanna D, Khanna PP, Furst DE. COX-2 controversy: Where are we and where do we go from here? [J]. Inflammopharmacology, 2005, 13: 395-402.
38. Shimizu T, Radmark 0, Samuelsson B. Enzyme with dual lipoxygenase activities catalyzes leukotriene A4 synthesis from arachidonic-acid [J]. Proc Natl Acad Sci USA, 1984, 81: 689-693.
39. Ford-Hutchinson AW, Gresser M, Young RN. 5-Lipoxygenase [J]. Annu Rev Biochem, 1994, 63: 383-417.
40. Crawley GC, Dowell RI, Edwards PN, et al. Methoxytet rahydropyrans -a new series of selective and orally potent 5-lipoxygenase inhibitors [J]. J Med Chem, 1992, 35: 2600-2609.
41. Delorme D, Ducharme Y, Brideau C, et al. Dioxalbicyclooctanyl naphthalenenitriles as nonredox 5-lipoxygenase inhibitors: Structure-activity relationship study directed toward the improvement of metabolic stability [J]. J Med Chem, 1996, 39: 3951-3970.
42. Wenzel SE, Kamada AK. Zileuton: The first 5-lipoxygenase inhibitor for the treatment of asthma [J]. Ann Pharmacother, 1996, 30: 858-864.
43. Lehnigk B, Rabe KF, Dent G et al. Effects of a 5-lipoxygenase inhibitor, ABT-761, on exercise-induced bronchoconstriction and urinary LTE4 in asthmatic patients [J]. Eur Respir J, 1998, 11: 617-623.
44. Miller DK, Gillard JW, Vickers PJ, et al. Identification and isolation of a membrane-protein necessary for leukotriene production [J]. Nature, 1990, 343: 278-281.
45. Tsuji F, Old K, Fujisawa K, et al. Involvement of leukotriene B4 in arthritis models [J]. Life Sci, 1998, 64: 151-156.
46. Penning TD. Inhibitors of leukotriene A4 (LTA4) hydrolase as potential anti-inflammatory agents [J]. Curr Pharm Des, 2001, 7: 163-179.
47. Penning TD, Chandrakumar NS, Desai BN, et al. Synthesis of imidazopyridines and purines as potent inhibitors of leukotriene A4 hydrolase [J]. Bioorg Med Chem Lett, 2003, 13: 1137-1139.
48. Grice CA, Tays KL, Savall BM, et al. Identification of a potent, selective, and orally active leukotriene A4 hydrolase inhibitor with anti-inflammatory activity [J]. J Med Chem, 2008, 51: 4150-4169.
49. Ye B, Bauman J, Chen M, et al. Synthesis of N-alkyl glycine amides as potent inhibitors of leukotriene A4 hydrolase [J]. Bioorg Med Chem Lett, 2008, 18: 3891-3894.
50. Haeggstrom JZ. Leukotriene A4 hydrolase/aminopeptidase, the gatekeeper of chemotactic leukotriene B4 biosynthesis [J]. 3 Biol Chem, 2004, 279: 50639-50642.
51. Thunnissen MM, Andersson B, Samuelsson B, et al. Crystal structures of leukotriene A4 hydrolase in complex with captopril and two competitive tight-binding inhibitors [J]. FASEB J, 2002, 16: 1648-1650.
52. Schrattenholz A, Soskic V. What does systems biology mean for drug development? [J]. Curr Med Chem, 2008, 15: 1520-1528.
53. Yang K, Bai HJ, Ouyang Q, et al. Finding multiple target optimal intervention in disease-related molecular network [J]. Mol Syst Biol, 2008, 4: 228.
54. Csermely R Strong links are important, but weak links stabilize them [J]. Trends Biochem Sci, 2004, 29: 331-334.
55. Li CY, Mao XZ, Wei ER Genes and (common) pathways underlying drug addiction [J]. PLoS Comput Biol, 2008, 4: 28-34.
56. de Gaetano G Donati MB, Cerletti C. Prevention of thrombosis and vascular inflammation: Benefits and limitations of selective or combined COX-1, COX-2 and 5-LOX inhibitors [J]. Trends Pharmacol Sci, 2003, 24: 245-252.
57. Bannwarth B. Is licofelone, a dual inbibitor of cyclo-ozygenase and 5-lipoxygenase, a promising alternative in anti-inflammatory therapy 7 [J]. Fundam Clin Pharmacol, 2004, 18: 125-130.
58. Kolasa T, Brooks CD, Rodriques KE, et al. Nonsteroidal anti-inflammatory drugs as scaffolds for the design of 5-lipoxygenase inhibitors [J]. J Med Chem, 1997, 40: 819-824.
59. Beers SA, Malloy BA, Wu W, et al. N-(5-substituted) thio phene-2-alkylsulfonamides as potent inhibitors of 5-lipozy-genase [J]. Bioorg Med Chem, 1997, 5: 779-786.
60. de Leval X, Julemont F, Delarge 3, et al. New trends in dual 5-LOX/COX inhibition [J]. Cun Med Chem, 2002, 9: 941-962.
61. Ulbrich H, Fiebich B, Dannhardt G. Cyclooxygenase-1/2 (COX-l/COX-2) and 5-lipoxygenase (5-LOX) inhibitors of the 6, 7-diary1-2, 3-1H- dihydropyrrolizine type [J]. Eur J Med Chem, 2002, 37: 953-959.
62. Yang K, Ma WZ, Liang HH, et al. Dynamic simulations on the arachidonic acid metabolic network [J]. PLoS Comput Biol, 2007, 3: 523-530.
63. Chen 3, Lai LH. Pocket v.2: Further developments on receptor-based pharmacophore modeling [J]. J Cbem Inf Model, 2006,46: 2684-2691.
64. Wei DG Hang XL, Zhou L, et al. Discovery of multitarget inhibitors by combining molecular docking with common pharmacophore matching [J]. J Med Chem, 2008, 51: 7882-7888.